

## Huntington's disease therapeutics conference 2019 - Day 2

New tools to bridge the gap between the lab and patients in our update from day 2 of the 2019 HD Therapeutics conference



By Joel Stanton and Dr Jeff Carroll February 28, 2019

Edited by Professor Ed Wild

**J**eff and Ed report from the Huntington's Disease Therapeutics Conference - the biggest annual gathering of HD researchers. This year's conference is bigger and more exciting than ever.

Read about Day 1 [here](#).

## Advanced tools for translational research



*Lauren Byrne presenting changes in "biofluid" markers in the sequence of events in HD*

Morning everyone! The second day of the 2019 HD Therapeutics Conference is kicking off in Palm Springs. The first session is "advanced tools for translational research".

The first speaker today is Lauren Byrne from UCL who studies biomarkers in blood and cerebrospinal fluid. Byrne measured mutant Huntingtin in CSF, and neurofilament light protein in CSF and blood in 80 volunteers. **Neurofilament light** or NFL is a protein found in neurons and released when they are damaged. Byrne also did MRI scans to see how each biomarker predicts brain shrinkage. Surprisingly, neurofilament turns out to be a better


predictor the mHTT of clinical symptoms and brain volume. Changes in these “biofluid” markers were among the earliest detectable changes too, preceding imaging and clinical measures in the sequence of events in HD.

Byrne has now completed the 2-year follow ups from the HD-CSF study and shows that the NFL seems to be changing as expected over time, and can be measured using a new system that tests 4 molecules at once.

Next up is Amber Southwell, from UCF, who is also interested in developing tools to quantify mutant huntingtin in the spinal fluid. Southwell’s team was the first to show that when mice are treated with a Huntingtin lowering therapy - specifically an ASO from Ionis Pharma - levels of mutant Huntingtin in the spinal fluid are reduced. This is important - it means that when we treat human HD patients with Huntingtin lowering drugs, we’d predict that the levels of mutant Huntingtin in the spinal fluid will go down. This is one of the things reserarchers mean when they say a measurement is a “biomarker”.

Southwell’s team is doing a cool series of experiments with mice that have no Huntingtin in specific types of brain cells. This is enabling them to map the exact type of brain cell responsible for releasing mutant Huntingtin into the spinal fluid. They’re also conducting another set of experiments focused on understanding the exact process by which mutant Huntingtin makes its way from brain cells called neurons into the spinal fluid. One process of brain bathing called “glymphatic clearance” seems likely to play a role in mutant Huntingtin making it’s way into the spinal fluid.

Next is David Salzman of sRNAlytics, a company that investigates the use of RNA to study diseases. RNA is the single-stranded cousin of DNA. Cells use RNA for many functions, most famously as the “working copy” of genes they want to switch on. That’s called messenger RNA. Less famously, cells produce many small RNA molecules that help in the regulation of gene switching. They have names like microRNA and there are lots of different ones. We understand genes as recipes for proteins pretty well, but micro RNAs are much morel mysterious at the moment.



*A panel of 60 small RNAs in CSF can distinguish between Huntington's, Alzheimer's and Parkinson's with decent accuracy, but more work is needed to understand how such biomarkers might help is develop treatments*

SRNAlytics identifies patterns of small RNA changes and uses artificial intelligence algorithms to identify what part of the body they come from, and how they change in different diseases. A panel of 60 small RNAs in CSF can apparently distinguish between Huntington's, Alzheimer's and Parkinson's with decent accuracy. Two small RNAs are of particular interest in HD, but it's important to understand exactly what they do in healthy and HD brains in order to figure out their value as possible biomarkers.

## **New animal models**

Guoping Feng, from MIT, is up next. His lab is working on developing new primate models of HD. He says mice are very useful, but they don't have all the same brain regions as humans, so we need to study more sophisticated brains as well. It used to be difficult to impossible to genetically modify primates, like monkeys, but new genome engineering tools make it possible. Tools like CRISPR/Cas9 allow precise DNA edits to be made to the DNA of monkey embryos. Feng's lab is one of the world's best at making changes to primate DNA. He describes that they've learned from human IVF clinics the best ways to keep primate embryos healthy. Feng's lab has generated a novel monkey model of a genetic form of autism. These monkeys have very interesting behaviors that really resemble humans with Autism, including altered social behaviors. They are now working to develop a monkey model of Huntington's Disease, and have conducted initial experiments suggesting it should be possible.

Hideyuki Okano, of Keio University, also works on primate models of human diseases - specifically Marmosets. His lab has genetically modified Marmosets to have a form of Parkinson's Disease caused by a genetic mutation. These animals have symptoms very close to those observed in Parkinson's Disease patients, including a very challenging sleep condition called REM sleep behavior disorder (RBD). They also have tremors and walking problems that resemble Parkinson's Disease patients. It's a good argument for using more sophisticated animals to model progressive brain diseases. Okano's lab is now developing techniques to generate similar models for Huntington's Disease.

That's all for today! Be sure to check out our write up of day [1](#) here and stand by for our final roundup tomorrow.

---

*Ed Wild, HDBuzz cofounder, is Lauren Byrne's PhD supervisor and line manager at UCL Huntington's disease Centre [For more information about our disclosure policy see our FAQ...](#)*

---

**CSF** A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.

**Parkinson's Disease** A neurodegenerative disease that, like HD, involves motor coordination problems

**messenger RNA** A message molecule, based on DNA, used by cells as the final set of instructions for making a protein.

**therapeutics** treatments

**CRISPR** A system for editing DNA in precise ways

**biomarker** a test of any kind - including blood tests, thinking tests and brain scans - that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable.

**neuron** Brain cells that store and transmit information

**embryo** the earliest stage during the development of a baby, when it consists of just a few cells

**primate** a group of mammal species including monkeys, apes and humans

**genome** the name given to all the genes that contain the complete instructions for making a person or other organism

**magnetic resonance** A technique using powerful magnetic fields to produce detailed images of the brain in living humans and animals

**ASOs** A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene

**In vitro fertilization** A medical procedure where eggs and sperm are combined in the laboratory, then embryos are implanted in the mother's womb.

**RNA** the chemical, similar to DNA, that makes up the 'message' molecules that cells use as working copies of genes, when manufacturing proteins.

---

© HDBuzz 2011-2024. HDBuzz content is free to share, under a Creative Commons Attribution-ShareAlike 3.0 Unported License.

HDBuzz is not a source of medical advice. For more information visit [hdbuzz.net](https://hdbuzz.net)

Generated on January 16, 2024 — Downloaded from <https://en.hdbuzz.net/269>